All In Biotech

Drug Trial Radar · NCT07596849

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Jun 10, 2026

Primary completion

Jun 2028

Study completion May 2030

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
May 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Conditions

  • Graves Disease

Interventions

  • efgartigimod PH20 SCBiological

    Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

  • Placebo PH20 SCOther

    Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part ATime frame: up to 24 weeks (part A)

Locations

51 sites in 14 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • AZORG Ziekenhuis

    Aalst, Oost-Vlass, Belgium · Recruiting

  • Medical Center Tonus - 2013 OOD

    Pazardzhik, Bulgaria · Recruiting

  • DCC Pulmed

    Plovdiv, Bulgaria · Recruiting

  • Multiprofile Hospital for Active Treatment Hadzhi Dimitar OOD

    Sliven, Bulgaria · Recruiting

  • Medical Center Kalimat

    Sofia, Bulgaria · Recruiting

  • Diagnostic Consultative Center Ekvita OOD

    Varna, Bulgaria · Recruiting

  • MC Klinika Nova

    Varna, Bulgaria · Recruiting

  • Multi-Profile District Hospital for Active Treatment Dr. Stefan Cherkezov

    Veliko Tarnovo, Bulgaria · Recruiting

  • TLC Diabetes and Endocrinology Clinic

    Surrey, Canada · Recruiting

  • Endocrinologie Oasis

    Montreal, Quebec, Canada · Recruiting

  • Nordsjaellands Hospital - Hillerod

    Hillerød, Capital Region, Denmark · Recruiting

  • High Technology Hospital Medcenter LLC

    Batumi, Georgia · Recruiting

  • First Medical Clinic Ltd

    Tbilisi, Georgia · Recruiting

  • LTD MediClub Georgia

    Tbilisi, Georgia · Recruiting

  • Institut fuer Praeventive Medizin & Klinische Forschung

    Magdeburg, Germany · Recruiting

  • Evangelismos Hospital

    Athens, Greece · Recruiting

  • Athens Medical Center

    Athens, Greece · Recruiting

  • AOU Ospedali Riuniti di Ancona Umberto I-G.M. Lancisi-G. Salesi

    Ancona, Italy · Recruiting

  • Aso Iizuka Hospital

    Iizuka, Japan · Recruiting

  • Nippon Medical School Musashikosugi Hospital

    Kawasaki, Japan · Recruiting

  • Hospital of University of Occupational and Environmental Health

    Kitakyushu, Japan · Recruiting

  • National Hospital Organization Kyoto Medical Center

    Kyoto, Japan · Recruiting

  • Nagasaki University Hospital

    Nagasaki, Japan · Recruiting

  • Ito Hospital

    Shibuya City, Japan · Recruiting

  • SHOWA Medical University Northern Yokohama Hospital

    Yokohama, Japan · Recruiting

  • Tottori University Hospital

    Yonago, Japan · Recruiting

  • Okayama University Hospital

    Okayama, Okayama-ken, Japan · Recruiting

  • Juntendo University Hospital

    Bunkyō-Ku, Tokyo, Japan · Recruiting

  • Toho University Omori Medical Center

    Ōta-ku, Tokyo, Japan · Recruiting

  • LTD M & M Centers

    Adazi, Latvia · Recruiting

  • Veselibas centrs 4

    Riga, Latvia · Recruiting

  • Klaipeda's University Hospital

    Klaipėda, Lithuania · Recruiting

  • Hospital of Lithuanian University of Health Sciences Kaunas

    Kaunas, Kauno, Lithuania · Recruiting

  • Centrum Medyczne INTERCOR Sp. z o.o.

    Bydgoszcz, Poland · Recruiting

  • DIABET Centrum Medyczne s.c.

    Chrzanów, Poland · Recruiting

  • ETG Lublin

    Lublin, Poland · Recruiting

  • Reumed Sp Z O.O.

    Lublin, Poland · Recruiting

  • NZOZ GynCentrum - Oddzial Warszawa

    Warsaw, Poland · Recruiting

  • ETG JustMed

    Warsaw, Poland · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.